Stay Updated
Menu

For Your Patients

Shire provides support programs for your patients

FREEDOM OF CHOICE™

Enroll your eligible patients in the VONVENDI® [von Willebrand factor (Recombinant)] Free Trial Program.

  • Download the enrollment form, and complete it with your patient
  • Fax the completed form to Shire's Hematology Support Center (HSC) at 1-866-467-7740

By enrolling in the FREEDOM OF CHOICE Free Trial Program for VONVENDI, your patients may be eligible to receive 3 free doses of VONVENDI* along with educational resources.

*Free Trial Program is for new VONVENDI patients only. Participants must receive consultation and approval from a healthcare provider.

CoPay Program

Do your patients need help paying for VONVENDI? We've Got You Covered™

Shire's CoPay Assistance Program offers financial assistance to eligible patients.

If your patients qualify, they may:

  • Save up to $12,000 every 12 months on VONVENDI*
  • Receive reimbursement for their portion of their medication costs

Your patients may be eligible for CoPay assistance if:

  • They are age 18 or older and are starting or receiving VONVENDI for von Willebrand disease
  • They have commercial insurance that covers medication costs for VONVENDI and allows for copay or coinsurance assistance

*Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

Must be age 18 or older and have a current prescription for VONVENDI with an ICD9 or ICD10, as applicable, of von Willebrand disease.

Not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law.

Spanish Resources

Shire’s Bilingual Health Educators

Shire’s Bilingual Health Educators can help connect the Spanish-speaking community with the bleeding disorders community. They can answer questions, provide culturally appropriate educational programs, and help patients navigate a complicated healthcare system. For more information contact a local Shire representative.

Insurance Support

Shire provides support services for your practice

Stay Updated

Stay up to date with the latest news and information

See LessMore

Indications VONVENDI [von Willebrand factor (recombinant)] is a recombinant von…

Detailed Important Risk Information Do not use VONVENDI in patients who have had life-threatening hypersensitivity reactions…

Indications

VONVENDI [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor (rVWF) indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding

Detailed Important Risk Information

CONTRAINDICATIONS

Do not use VONVENDI in patients who have had life-threatening hypersensitivity reactions to VONVENDI or its components (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins).

VONVENDI® [von Willebrand factor (recombinant)] Important Information

Indications

VONVENDI [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor (rVWF) indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding

Detailed Important Risk Information

CONTRAINDICATIONS

Do not use VONVENDI in patients who have had life-threatening hypersensitivity reactions to VONVENDI or its components (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins).

WARNINGS AND PRECAUTIONS

Embolism and Thrombosis

Thromboembolic reactions, including disseminated intravascular coagulation, venous thrombosis, pulmonary embolism, myocardial infarction, and stroke, can occur, particularly in patients with known risk factors for thrombosis, including low ADAMTS13 levels. Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope, and institute prophylaxis measures against thromboembolism based on current recommendations.

In patients requiring frequent doses of VONVENDI in combination with recombinant factor VIII, monitor plasma levels for FVIII:C activity because sustained excessive factor VIII plasma levels can increase the risk of thromboembolic events.

One out of 80 VWD patients treated with VONVENDI in clinical trials developed proximal deep vein thrombosis in perioperative period after undergoing total hip replacement surgery.

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, may occur. Symptoms can include anaphylactic shock, generalized urticaria, angioedema, chest tightness, hypotension, shock, lethargy, nausea, vomiting, paresthesia, pruritus, restlessness, wheezing and/or acute respiratory distress. Discontinue VONVENDI if hypersensitivity symptoms occur and administer appropriate emergency treatment.

Neutralizing Antibodies (Inhibitors)

Inhibitors to von Willebrand factor and/or factor VIII can occur. If the expected plasma levels of VWF activity (VWF:RCo) are not attained, perform an appropriate assay to determine if anti-VWF or anti-factor VIII inhibitors are present. Consider other therapeutic options and direct the patient to a physician with experience in the care of either VWD or hemophilia A.

In patients with high levels of inhibitors to VWF or factor VIII, VONVENDI therapy may not be effective and infusion of this protein may lead to severe hypersensitivity reactions. Since inhibitor antibodies can occur concomitantly with anaphylactic reactions, evaluate patients experiencing an anaphylactic reaction for the presence of inhibitors.

ADVERSE REACTIONS

In clinical trials, the most common adverse reactions observed in ≥2% of subjects (n=80) were generalized pruritus, vomiting, nausea, dizziness and vertigo.

One subject treated with VONVENDI in perioperative setting developed deep vein thrombosis after undergoing total hip replacement surgery.

Please see VONVENDI full Prescribing Information.